| Year |
Citation |
Score |
| 2024 |
Deng W, Chong B, Addington J, Bearden CE, Cadenhead KS, Cornblatt BA, Keshavan M, Mathalon DH, Perkins DO, Stone W, Walker EF, Woods SW, Cannon TD. Beyond the Descriptive: A Comprehensive, Multi-domain Validation of Symptom Trajectories for Individuals at Clinical High Risk for Psychosis. Biological Psychiatry. Cognitive Neuroscience and Neuroimaging. PMID 39260565 DOI: 10.1016/j.bpsc.2024.08.020 |
0.311 |
|
| 2024 |
Schleifer CH, Chang SE, Amir CM, O'Hora KP, Fung H, Kang JWD, Kushan-Wells L, Daly E, Di Fabio F, Frascarelli M, Gudbrandsen M, Kates WR, Murphy D, Addington J, Anticevic A, ... ... Perkins DO, et al. Unique functional neuroimaging signatures of genetic versus clinical high risk for psychosis. Biological Psychiatry. PMID 39181389 DOI: 10.1016/j.biopsych.2024.08.010 |
0.3 |
|
| 2024 |
Chintoh A, Liu L, Braun A, Akseer S, Bearden CE, Cadenhead KS, Cornblatt BA, Keshavan M, Mathalon DH, McGlashan TH, Perkins DO, Seidman LJ, Stone W, Tsuang MT, Walker EF, et al. Sex differences in clinical presentation in youth at high risk for psychosis who transition to psychosis. Schizophrenia Research. 271: 153-160. PMID 39029145 DOI: 10.1016/j.schres.2024.07.030 |
0.314 |
|
| 2024 |
Cowan HR, Williams TF, Mittal VA, Addington J, Bearden CE, Cadenhead KS, Cannon TD, Cornblatt BA, Keshevan M, Perkins DO, Mathalon DH, Stone W, Woods SW, Walker EF. The Complex Latent Structure of Attenuated Psychotic Symptoms: Hierarchical and Bifactor Models of SIPS Symptoms Replicated in Two Large Samples at Clinical High Risk for Psychosis. Schizophrenia Bulletin. PMID 38728417 DOI: 10.1093/schbul/sbae042 |
0.3 |
|
| 2024 |
Wannan CMJ, Nelson B, Addington J, Allott K, Anticevic A, Arango C, Baker JT, Bearden CE, Billah T, Bouix S, Broome MR, Buccilli K, Cadenhead KS, Calkins ME, Cannon TD, ... ... Perkins DO, et al. Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis. Schizophrenia Bulletin. PMID 38451304 DOI: 10.1093/schbul/sbae011 |
0.327 |
|
| 2024 |
Healy C, Byrne J, Raj Suasi S, Föcking M, Mongan D, Kodosaki E, Heurich-Sevcenco M, Cagney G, Wynne K, Bearden CE, Woods SW, Cornblatt B, Mathalon D, Stone W, Cannon TD, ... ... Perkins D, et al. Differential expression of haptoglobin in individuals at clinical high risk of psychosis and its association with global functioning and clinical symptoms. Brain, Behavior, and Immunity. PMID 38219978 DOI: 10.1016/j.bbi.2023.12.018 |
0.355 |
|
| 2023 |
Devoe DJ, Lui L, Cannon TD, Cadenhead KS, Cornblatt BA, Keshavan M, McGlashan TH, Perkins DO, Seidman LJ, Stone WS, Tsuang MT, Woods SW, Walker EF, Mathalon DH, Bearden CE, et al. The impact of early factors on persistent negative symptoms in youth at clinical high risk for psychosis. Frontiers in Psychiatry. 14: 1125168. PMID 37293402 DOI: 10.3389/fpsyt.2023.1125168 |
0.328 |
|
| 2022 |
Sefik E, Boamah M, Addington J, Bearden CE, Cadenhead KS, Cornblatt BA, Keshavan MS, Mathalon DH, Perkins DO, Stone WS, Tsuang MT, Woods SW, Cannon TD, Walker EF. Sex- and Age-Specific Deviations in Cerebellar Structure and Their Link With Symptom Dimensions and Clinical Outcome in Individuals at Clinical High Risk for Psychosis. Schizophrenia Bulletin. PMID 36394426 DOI: 10.1093/schbul/sbac169 |
0.321 |
|
| 2022 |
Barbato M, Liu L, Bearden CE, Cadenhead KS, Cornblatt BA, Keshavan M, Mathalon DH, McGlashan TH, Perkins DO, Seidman LJ, Stone W, Tsuang MT, Walker EF, Woods SW, Cannon TD, et al. Migrant status, clinical symptoms and functional outcome in youth at clinical high risk for psychosis: findings from the NAPLS-3 study. Social Psychiatry and Psychiatric Epidemiology. PMID 36348056 DOI: 10.1007/s00127-022-02383-y |
0.331 |
|
| 2022 |
Santesteban-Echarri O, Sandel D, Liu L, Bearden CE, Cadenhead KS, Cannon TD, Cornblatt BA, Keshavan M, Mathalon DH, McGlashan TH, Perkins DO, Seidman LJ, Stone WS, Tsuang MT, Walker EF, et al. Family history of psychosis in youth at clinical high risk: A replication study. Psychiatry Research. 311: 114480. PMID 35245743 DOI: 10.1016/j.psychres.2022.114480 |
0.308 |
|
| 2020 |
Cadenhead KS, Duncan E, Addington J, Bearden C, Cannon TD, Cornblatt BA, Mathalon D, McGlashan TH, Perkins DO, Seidman LJ, Tsuang M, Walker EF, Woods SW, Bauchman P, Belger A, et al. Evidence of Slow Neural Processing, Developmental Differences and Sensitivity to Cannabis Effects in a Sample at Clinical High Risk for Psychosis From the NAPLS Consortium Assessed With the Human Startle Paradigm. Frontiers in Psychiatry. 11: 833. PMID 33005152 DOI: 10.3389/Fpsyt.2020.00833 |
0.417 |
|
| 2020 |
Calkins ME, Woods SW, Bearden CE, Liu L, Moore TM, Cadenhead KS, Cannon TD, Cornblatt BA, McGlashan TH, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, Mathalon DH, Keshavan M, et al. Concordance and factor structure of subthreshold positive symptoms in youth at clinical high risk for psychosis. Schizophrenia Research. PMID 32943313 DOI: 10.1016/J.Schres.2020.08.014 |
0.403 |
|
| 2020 |
Perkins DO, Jeffries CD, Do KQ. Potential Roles of Redox Dysregulation in the Development of Schizophrenia. Biological Psychiatry. PMID 32560962 DOI: 10.1016/J.Biopsych.2020.03.016 |
0.399 |
|
| 2020 |
Woods SW, Bearden CE, Sabb FW, Stone WS, Torous J, Cornblatt BA, Perkins DO, Cadenhead KS, Addington J, Powers AR, Mathalon DH, Calkins ME, Wolf DH, Corcoran CM, Horton LE, et al. Counterpoint. Early intervention for psychosis risk syndromes: Minimizing risk and maximizing benefit. Schizophrenia Research. PMID 32402605 DOI: 10.1016/J.Schres.2020.04.020 |
0.342 |
|
| 2020 |
Devoe DJ, Lu L, Cannon TD, Cadenhead KS, Cornblatt BA, McGlashan TH, Perkins DO, Seidman LJ, Tsuang MT, Woods SW, Walker EF, Mathalon DH, Bearden CE, Addington J. Persistent negative symptoms in youth at clinical high risk for psychosis: A longitudinal study. Schizophrenia Research. PMID 32362460 DOI: 10.1016/J.Schres.2020.04.004 |
0.454 |
|
| 2020 |
Addington J, Liu L, Brummitt K, Bearden CE, Cadenhead KS, Cornblatt BA, Keshavan M, Mathalon DH, McGlashan TH, Perkins DO, Seidman LJ, Stone W, Tsuang MT, Walker EF, Woods SW, et al. North American Prodrome Longitudinal Study (NAPLS 3): Methods and baseline description. Schizophrenia Research. PMID 32317224 DOI: 10.1016/J.Schres.2020.04.010 |
0.304 |
|
| 2020 |
Roach BJ, Hamilton HK, Bachman P, Belger A, Carrión RE, Duncan E, Johannesen J, Kenney JG, Light G, Niznikiewicz M, Addington J, Bearden CE, Owens EM, Cadenhead KS, Cannon TD, ... ... Perkins DO, et al. Stability of mismatch negativity event-related potentials in a multisite study. International Journal of Methods in Psychiatric Research. e1819. PMID 32232944 DOI: 10.1002/Mpr.1819 |
0.348 |
|
| 2020 |
Cullen AE, Addington J, Bearden CE, Stone WS, Seidman LJ, Cadenhead KS, Cannon TD, Cornblatt BA, Mathalon DH, McGlashan TH, Perkins DO, Tsuang MT, Woods SW, Walker EF. Stressor-Cortisol Concordance Among Individuals at Clinical High-Risk for Psychosis: Novel Findings from the NAPLS Cohort. Psychoneuroendocrinology. 115: 104649. PMID 32197198 DOI: 10.1016/J.Psyneuen.2020.104649 |
0.343 |
|
| 2020 |
Velikonja T, Velthorst E, Zinberg J, Cannon TD, Cornblatt BA, Perkins DO, Cadenhead KS, Tsuang MT, Addington J, Woods SW, McGlashan T, Mathalon DH, Stone W, Keshavan M, Seidman L, et al. Childhood trauma and cognitive functioning in individuals at clinical high risk (CHR) for psychosis. Development and Psychopathology. 1-12. PMID 31959269 DOI: 10.1017/S095457941900155X |
0.354 |
|
| 2020 |
Worthington MA, Miklowitz DJ, O'Brien M, Addington J, Bearden CE, Cadenhead KS, Cornblatt BA, Mathalon DH, McGlashan TH, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, Woods SW, Cannon TD. Selection for psychosocial treatment for youth at clinical high risk for psychosis based on the North American Prodrome Longitudinal Study individualized risk calculator. Early Intervention in Psychiatry. PMID 31943807 DOI: 10.1111/Eip.12914 |
0.411 |
|
| 2020 |
Worthington M, Addington J, Bearden C, Cadenhead K, Cornblatt B, Mathalon D, McGlashan T, Perkins D, Seidman L, Tsuang M, Walker E, Woods S, Cannon T. T116. PREDICTION OF REMISSION IN NON-CONVERTING INDIVIDUALS AT CLINICAL HIGH RISK FOR PSYCHOSIS Schizophrenia Bulletin. 46: S274-S275. DOI: 10.1093/Schbul/Sbaa029.676 |
0.389 |
|
| 2020 |
Hamilton H, Roach B, Bachman P, Belger A, Carrion R, Johannesen J, Light G, Niznikiewicz M, Addington J, Bearden C, Cadenhead K, Cornblatt B, McGlashan T, Perkins D, Seidman L, et al. O10.2. DEFICIENT VISUAL ODDBALL STIMULUS PROCESSING PREDICTS PSYCHOSIS ONSET: RESULTS FROM THE NORTH AMERICAN PRODROME LONGITUDINAL STUDY Schizophrenia Bulletin. 46: S24-S25. DOI: 10.1093/Schbul/Sbaa028.056 |
0.36 |
|
| 2020 |
Di Biase M, Cetin Karayumak S, Zalesky A, Kubicki M, Rathi Y, Lyons MG, Bouix S, Billah T, Higger M, Anticevic A, Addington J, Bearden CE, Cornblatt BA, Keshavan MS, Mathalon DH, ... ... Perkins DO, et al. O5.6. ADVANCED DIFFUSION IMAGING IN PSYCHOSIS RISK: A CROSS-SECTIONAL AND LONGITUDINAL STUDY OF WHITE MATTER DEVELOPMENT Schizophrenia Bulletin. 46: S13-S13. DOI: 10.1093/Schbul/Sbaa028.029 |
0.36 |
|
| 2019 |
Yoviene Sykes LA, Ferrara M, Addington J, Bearden CE, Cadenhead KS, Cannon TD, Cornblatt BA, Perkins DO, Mathalon DH, Seidman LJ, Tsuang MT, Walker EF, McGlashan TH, Woodberry KA, Powers AR, et al. Predictive validity of conversion from the clinical high risk syndrome to frank psychosis. Schizophrenia Research. PMID 31864837 DOI: 10.1016/J.Schres.2019.12.002 |
0.382 |
|
| 2019 |
Powers AR, Addington J, Perkins DO, Bearden CE, Cadenhead KS, Cannon TD, Cornblatt BA, Mathalon DH, Seidman LJ, Tsuang MT, Walker EF, McGlashan TH, Woods SW. Duration of the psychosis prodrome. Schizophrenia Research. PMID 31806523 DOI: 10.1016/J.Schres.2019.10.051 |
0.351 |
|
| 2019 |
Perkins DO, Olde Loohuis L, Barbee J, Ford J, Jeffries CD, Addington J, Bearden CE, Cadenhead KS, Cannon TD, Cornblatt BA, Mathalon DH, McGlashan TH, Seidman LJ, Tsuang M, Walker EF, et al. Polygenic Risk Score Contribution to Psychosis Prediction in a Target Population of Persons at Clinical High Risk. The American Journal of Psychiatry. appiajp201918060721. PMID 31711302 DOI: 10.1176/Appi.Ajp.2019.18060721 |
0.368 |
|
| 2019 |
Bigdeli TB, Genovese G, Georgakopoulos P, Meyers JL, Peterson RE, Iyegbe CO, Medeiros H, Valderrama J, Achtyes ED, Kotov R, Stahl EA, Abbott C, Azevedo MH, Belliveau RA, Bevilacqua E, ... ... Perkins DO, et al. Contributions of common genetic variants to risk of schizophrenia among individuals of African and Latino ancestry. Molecular Psychiatry. PMID 31591465 DOI: 10.1038/S41380-019-0517-Y |
0.368 |
|
| 2019 |
Allswede DM, Addington J, Bearden CE, Cadenhead KS, Cornblatt BA, Mathalon DH, McGlashan T, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, Woods SW, Cannon TD. Characterizing Covariant Trajectories of Individuals at Clinical High Risk for Psychosis Across Symptomatic and Functional Domains. The American Journal of Psychiatry. appiajp201918111290. PMID 31509005 DOI: 10.1176/Appi.Ajp.2019.18111290 |
0.416 |
|
| 2019 |
Hamilton HK, Roach BJ, Bachman PM, Belger A, Carrion RE, Duncan E, Johannesen JK, Light GA, Niznikiewicz MA, Addington J, Bearden CE, Cadenhead KS, Cornblatt BA, McGlashan TH, Perkins DO, et al. Association Between P300 Responses to Auditory Oddball Stimuli and Clinical Outcomes in the Psychosis Risk Syndrome. Jama Psychiatry. PMID 31389974 DOI: 10.1001/Jamapsychiatry.2019.2135 |
0.458 |
|
| 2019 |
Goines KB, LoPilato AM, Addington J, Bearden CE, Cadenhead KS, Cannon TD, Cornblatt BA, Mathalon DH, McGlashan TH, Perkins DO, Tsuang MT, Woods SW, Walker EF. Sleep problems and attenuated psychotic symptoms in youth at clinical high-risk for psychosis. Psychiatry Research. 112492. PMID 31387769 DOI: 10.1016/J.Psychres.2019.112492 |
0.321 |
|
| 2019 |
Chung Y, Allswede D, Addington J, Bearden CE, Cadenhead K, Cornblatt B, Mathalon DH, McGlashan T, Perkins D, Seidman LJ, Tsuang M, Walker E, Woods SW, McEwen S, van Erp TGM, et al. Cortical abnormalities in youth at clinical high-risk for psychosis: Findings from the NAPLS2 cohort. Neuroimage. Clinical. 23: 101862. PMID 31150956 DOI: 10.1016/J.Nicl.2019.101862 |
0.409 |
|
| 2019 |
Shakeel MK, Lu L, Woods SW, Perkins DO, Addington J. Neurocognitive predictors of metacognition in individuals at clinical high risk for psychosis. Behavioural and Cognitive Psychotherapy. 1-5. PMID 30982487 DOI: 10.1017/S1352465819000328 |
0.456 |
|
| 2019 |
Dixon L, Jones N, Loewy R, Perkins D, Sale T, Huggins W, Hamilton C. Recommendations and Challenges of the Clinical Services Panel of the PhenX Early Psychosis Working Group. Psychiatric Services (Washington, D.C.). appips201800585. PMID 30966946 DOI: 10.1176/Appi.Ps.201800585 |
0.336 |
|
| 2019 |
Lauriello J, Perkins DO. Managing Transitions in Care and Adherence to Improve Outcomes in Schizophrenia. The Journal of Clinical Psychiatry. 80. PMID 30920189 DOI: 10.4088/Jcp.Al18010Wc1C |
0.375 |
|
| 2019 |
Foss-Feig JH, Velthorst E, Smith L, Reichenberg A, Addington J, Cadenhead KS, Cornblatt BA, Mathalon DH, McGlashan TH, Perkins DO, Seidman LJ, Stone WS, Keshavan M, Tsuang MT, Walker EF, et al. Clinical Profiles and Conversion Rates Among Young Individuals With Autism Spectrum Disorder Who Present to Clinical High Risk For Psychosis Services. Journal of the American Academy of Child and Adolescent Psychiatry. PMID 30797038 DOI: 10.1016/J.Jaac.2018.09.446 |
0.391 |
|
| 2019 |
Lauriello J, Perkins DO. Enhancing the Treatment of Patients With Schizophrenia Through Continuous Care. The Journal of Clinical Psychiatry. 80. PMID 30786179 DOI: 10.4088/Jcp.Al18010Ah2C |
0.407 |
|
| 2019 |
LoPilato AM, Goines K, Addington J, Bearden CE, Cadenhead KS, Cannon TD, Cornblatt BA, Mathalon DH, McGlashan TH, Seidman L, Perkins DO, Tsuang MT, Woods SW, Walker EF. Impact of childhood adversity on corticolimbic volumes in youth at clinical high-risk for psychosis. Schizophrenia Research. PMID 30745068 DOI: 10.1016/J.Schres.2019.01.048 |
0.387 |
|
| 2019 |
Chung Y, Addington J, Bearden CE, Cadenhead K, Cornblatt B, Mathalon DH, McGlashan T, Perkins D, Seidman LJ, Tsuang M, Walker E, Woods SW, McEwen S, van Erp TGM, Cannon TD, et al. Adding a neuroanatomical biomarker to an individualized risk calculator for psychosis: A proof-of-concept study. Schizophrenia Research. PMID 30745066 DOI: 10.1016/J.Schres.2019.01.026 |
0.325 |
|
| 2019 |
Perkins D. 33.3 The Psychosis Clinical-High Risk Syndrome: Ethical Issues And Practical Challenges In The Clinical Management Of A Syndrome Without A Name Schizophrenia Bulletin. 45. DOI: 10.1093/Schbul/Sbz022.139 |
0.31 |
|
| 2019 |
Devoe D, Liu L, Cadenhead K, Cannon T, Cornblatt B, McGlashan T, Perkins D, Seidman LJ, Tsuang M, Walker E, Woods S, Bearden C, Mathalon D, Addington J. S21. THE IMPACT OF PERSISTENT NEGATIVE SYMPTOMS ON FUNCTIONING AND DEFEATIST BELIEFS IN YOUTH AT CLINICAL HIGH RISK FOR PSYCHOSIS Schizophrenia Bulletin. 45: S313-S313. DOI: 10.1093/Schbul/Sbz020.566 |
0.412 |
|
| 2019 |
Kraus M, Walker T, Perkins D, Keefe R. T32. Intact Auditory Perception In Individuals At Clinical High Risk For Psychosis Schizophrenia Bulletin. 45. DOI: 10.1093/Schbul/Sbz019.312 |
0.342 |
|
| 2019 |
Kelsven S, Addington JM, Bearden CE, Cannon TD, Cornblatt B, Mathalon DH, McGlashan TH, Perkins DO, Seidman LJ, Walker EF, Woods SW, Cadenhead KS. T13. THE ASSOCIATION BETWEEN CHILDHOOD TRAUMA AND INFLAMMATION IN YOUTH AT CLINICAL HIGH RISK FOR PSYCHOSIS Schizophrenia Bulletin. 45: S207-S208. DOI: 10.1093/Schbul/Sbz019.293 |
0.341 |
|
| 2019 |
Martin AS, Johannesen J, Roach B, Hamilton H, Bachman P, Belger A, Carrión R, Duncan E, Light G, Niznikiewicz M, Addington J, Bearden C, Cadenhead K, Cannon T, Cornblatt B, ... ... Perkins D, et al. S190. Does Cannabis Use Interact With Neurophysiological Vulnerability in the Early Expression of Psychosis and Conversion Status in Clinical High-Risk (CHR) Individuals? Biological Psychiatry. 85: S370-S371. DOI: 10.1016/J.Biopsych.2019.03.941 |
0.369 |
|
| 2019 |
Ramyead A, Roach B, Hamilton H, Addington J, Bachman P, Bearden C, Belger A, Cadenhead K, Cannon T, Carrion R, Cornblatt B, Duncan E, Johannesen J, Light G, McGlashan T, ... ... Perkins D, et al. O33. EEG Alpha Event-Related Desynchronization Deficits Predict Conversion to Psychosis in Individuals With the Psychosis Risk Syndrome Biological Psychiatry. 85: S119. DOI: 10.1016/J.Biopsych.2019.03.298 |
0.32 |
|
| 2018 |
Goldsmith DR, Haroon E, Miller AH, Addington J, Bearden C, Cadenhead K, Cannon T, Cornblatt B, Mathalon D, McGlashan T, Seidman L, Tsuang M, Woods SW, Walker EF, Perkins DO. Association of baseline inflammatory markers and the development of negative symptoms in individuals at clinical high risk for psychosis. Brain, Behavior, and Immunity. PMID 30496778 DOI: 10.1016/J.Bbi.2018.11.315 |
0.361 |
|
| 2018 |
Ward HB, Lawson MT, Addington J, Bearden CE, Cadenhead KS, Cannon TD, Cornblatt BA, Jeffries CD, Mathalon DH, McGlashan TH, Seidman LJ, Tsuang MT, Walker EF, Woods SW, Perkins DO. Tobacco use and psychosis risk in persons at clinical high risk. Early Intervention in Psychiatry. PMID 30362261 DOI: 10.1111/Eip.12751 |
0.373 |
|
| 2018 |
Carrión RE, Auther AM, McLaughlin D, Olsen R, Addington J, Bearden CE, Cadenhead KS, Cannon TD, Mathalon DH, McGlashan TH, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, Woods SW, et al. The Global Functioning: Social and Role Scales-Further Validation in a Large Sample of Adolescents and Young Adults at Clinical High Risk for Psychosis. Schizophrenia Bulletin. PMID 30351423 DOI: 10.1093/Schbul/Sby126 |
0.379 |
|
| 2018 |
Cadenhead KS, Minichino A, Kelsven S, Addington J, Bearden C, Cannon TD, Cornblatt BA, Mathalon D, McGlashan TH, Perkins DO, Seidman LJ, Tsuang M, Walker EF, Woods SW, Yao J, et al. Metabolic abnormalities and low dietary Omega 3 are associated with symptom severity and worse functioning prior to the onset of psychosis: Findings from the North American Prodrome Longitudinal Studies Consortium. Schizophrenia Research. PMID 30249470 DOI: 10.1016/J.Schres.2018.09.022 |
0.433 |
|
| 2018 |
Cao H, Chén OY, Chung Y, Forsyth JK, McEwen SC, Gee DG, Bearden CE, Addington J, Goodyear B, Cadenhead KS, Mirzakhanian H, Cornblatt BA, Carrión RE, Mathalon DH, McGlashan TH, ... Perkins DO, et al. Cerebello-thalamo-cortical hyperconnectivity as a state-independent functional neural signature for psychosis prediction and characterization. Nature Communications. 9: 3836. PMID 30242220 DOI: 10.1038/S41467-018-06350-7 |
0.403 |
|
| 2018 |
Shakeel MK, Lu L, Cannon TD, Cadenhead KS, Cornblatt BA, McGlashan TH, Perkins DO, Seidman LJ, Tsuang MT, Woods SW, Walker EF, Mathalon DH, Bearden CE, Addington J. Longitudinal changes in social cognition in individuals at clinical high risk for psychosis: An outcome based analysis. Schizophrenia Research. PMID 30181061 DOI: 10.1016/J.Schres.2018.08.032 |
0.334 |
|
| 2018 |
Addington J, Stowkowy J, Liu L, Cadenhead KS, Cannon TD, Cornblatt BA, McGlashan TH, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, Bearden CE, Mathalon DH, Santesteban-Echarri O, Woods SW. Clinical and functional characteristics of youth at clinical high-risk for psychosis who do not transition to psychosis. Psychological Medicine. 1-8. PMID 30176955 DOI: 10.1017/S0033291718002258 |
0.438 |
|
| 2018 |
Hampton JN, Trotman HD, Addington J, Bearden CE, Cadenhead KS, Cannon TD, Cornblatt BA, Mathalon DH, McGlashan TH, Tsuang MT, Perkins DO, Seidman LJ, Woods SW, Walker EF. The relation of atypical antipsychotic use and stress with weight in individuals at clinical high risk for psychosis. Stress and Health : Journal of the International Society For the Investigation of Stress. PMID 29956456 DOI: 10.1002/Smi.2819 |
0.322 |
|
| 2018 |
Davidson CA, Piskulic D, Addington J, Cadenhead KS, Cannon TD, Cornblatt BA, McGlashan TH, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, Bearden CE, Mathalon DH, Woods SW, Johannesen JK. Age-related trajectories of social cognition in youth at clinical high risk for psychosis: An exploratory study. Schizophrenia Research. PMID 29751984 DOI: 10.1016/J.Schres.2018.05.001 |
0.346 |
|
| 2018 |
Meyer-Kalos PS, Ludwig KA, Gaylord S, Perkins DO, Grewen K, Palsson OS, Burchinal M, Penn DL. Enhancing stress reactivity and wellbeing in early schizophrenia: A pilot study of individual coping awareness therapy (I-CAT). Schizophrenia Research. PMID 29735201 DOI: 10.1016/J.Schres.2018.04.039 |
0.367 |
|
| 2018 |
Webb JR, Addington J, Perkins DO, Bearden CE, Cadenhead KS, Cannon TD, Cornblatt BA, Heinssen RK, Seidman LJ, Woods SW. Erratum to: Specificity of incident diagnostic outcomes in patients at clinical high risk for psychosis Schizophrenia Bulletin. 44. PMID 29718467 DOI: 10.1093/Schbul/Sbx097 |
0.359 |
|
| 2018 |
Brodey BB, Girgis RR, Favorov OV, Addington J, Perkins DO, Bearden CE, Woods SW, Walker EF, Cornblatt BA, Brucato G, Walsh B, Elkin KA, Brodey IS. The Early Psychosis Screener (EPS): Quantitative validation against the SIPS using machine learning. Schizophrenia Research. PMID 29358019 DOI: 10.1016/J.Schres.2017.11.030 |
0.346 |
|
| 2018 |
Foss-Feig J, Velthorst E, Guillory S, Hamilton H, Roach B, Bachman P, Belger A, Carrion R, Duncan E, Johannesen J, Light G, Niznikiewicz M, Addington J, Cadenhead K, Cannon T, ... ... Perkins D, et al. F118. ARCHITECTURE OF PSYCHOSIS SYMPTOMS AND NEURAL PREDICTORS OF CONVERSION AMONG CLINICAL HIGH RISK INDIVIDUALS WITH AUTISM SPECTRUM DISORDER Schizophrenia Bulletin. 44: S266-S266. DOI: 10.1093/Schbul/Sby017.649 |
0.36 |
|
| 2018 |
Santesteban-Echarri O, Stowkowy J, Woods SW, Liu L, Cadenhead KS, Cannon TD, Cornblatt BA, McGlashan TH, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, Bearden CE, Mathalon DH, Addington JM. F32. DIFFERENCES BETWEEN YOUTH AT CLINICAL HIGH-RISK FOR PSYCHOSIS WHO DO NOT TRANSITION TO PSYCHOSIS: THE NORTH AMERICAN PRODROME LONGITUDINAL STUDY (NAPLS-2) Schizophrenia Bulletin. 44: S231-S231. DOI: 10.1093/Schbul/Sby017.563 |
0.393 |
|
| 2018 |
Cullen A, Cadenhead KS, Addington J, Bearden CE, Cannon T, Cornblatt BA, Mathalon D, McGlashan TH, Perkins DO, Seidman L, Stone WS, Tsuang M, Woods SW, Walker EF. O9.8. STRESS AND COGNITIVE FUNCTION AMONG INDIVIDUALS AT CLINICAL HIGH-RISK FOR PSYCHOSIS: FINDINGS FROM THE NAPLS COHORT Schizophrenia Bulletin. 44: S102-S102. DOI: 10.1093/Schbul/Sby015.252 |
0.351 |
|
| 2018 |
Goldsmith D, Miller A, Addington J, Bearden C, Cadenhead K, Cannon T, Cornblatt B, Mathalon D, McGlashan T, Perkins D, Tsuang M, Woods S, Walker E. F236. Association of Baseline Tumor Necrosis Factor and the Development of Negative Symptoms in Individuals at Clinical High Risk for Psychosis Biological Psychiatry. 83: S330-S331. DOI: 10.1016/J.Biopsych.2018.02.850 |
0.374 |
|
| 2017 |
Perkins DO. Improving Long-Term Outcomes in Patients With Schizophrenia: What Is the Evidence for Long-Acting Injectable Antipsychotics? The Journal of Clinical Psychiatry. 78: e1431. PMID 29345879 DOI: 10.4088/Jcp.Ot16046Tx1Cj |
0.362 |
|
| 2017 |
Ryan AT, Addington J, Bearden CE, Cadenhead KS, Cornblatt BA, Mathalon DH, McGlashan TH, Perkins DO, Seidman LJ, Tsuang MT, Woods SW, Cannon TD, Walker EF. Latent class cluster analysis of symptom ratings identifies distinct subgroups within the clinical high risk for psychosis syndrome. Schizophrenia Research. PMID 29279247 DOI: 10.1016/J.Schres.2017.12.001 |
0.396 |
|
| 2017 |
Brodey BB, Addington J, First MB, Perkins DO, Woods SW, Walker EF, Walsh B, Nieri JM, Nunn MB, Putz J, Brodey IS. The Early Psychosis Screener (EPS): Item development and qualitative validation. Schizophrenia Research. PMID 29254878 DOI: 10.1016/J.Schres.2017.11.027 |
0.304 |
|
| 2017 |
Healey KM, Penn DL, Perkins D, Woods SW, Keefe RSE, Addington J. Latent Profile Analysis and Conversion to Psychosis: Characterizing Subgroups to Enhance Risk Prediction. Schizophrenia Bulletin. PMID 29036587 DOI: 10.1093/Schbul/Sbx080 |
0.407 |
|
| 2017 |
Woods SW, Powers AR, Taylor JH, Davidson CA, Johannesen JK, Addington J, Perkins DO, Bearden CE, Cadenhead KS, Cannon TD, Cornblatt BA, Seidman LJ, Tsuang MT, Walker EF, McGlashan TH. Lack of Diagnostic Pluripotentiality in Patients at Clinical High Risk for Psychosis: Specificity of Comorbidity Persistence and Search for Pluripotential Subgroups. Schizophrenia Bulletin. PMID 29036402 DOI: 10.1093/Schbul/Sbx138 |
0.371 |
|
| 2017 |
Stowkowy J, Liu L, Cadenhead KS, Tsuang MT, Cannon TD, Cornblatt BA, McGlashan TH, Woods SW, Perkins DO, Seidman LJ, Walker EF, Bearden CE, Mathalon DH, Addington J. Exploration of clinical high-risk dropouts. Schizophrenia Research. PMID 28964651 DOI: 10.1016/J.Schres.2017.09.018 |
0.349 |
|
| 2017 |
Lu Y, Marshall C, Cadenhead KS, Cannon TD, Cornblatt BA, McGlashan TH, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, Woods SW, Bearden CE, Mathalon D, Addington J. Perceptual abnormalities in clinical high risk youth and the role of trauma, cannabis use and anxiety. Psychiatry Research. PMID 28886901 DOI: 10.1016/J.Psychres.2017.08.045 |
0.371 |
|
| 2017 |
Tarbox-Berry SI, Perkins DO, Woods SW, Addington J. Premorbid social adjustment and association with attenuated psychotic symptoms in clinical high-risk and help-seeking youth. Psychological Medicine. 1-15. PMID 28874223 DOI: 10.1017/S0033291717002343 |
0.406 |
|
| 2017 |
Georgopoulos G, Stowkowy J, Liu L, Cadenhead KS, Cannon TD, Cornblatt BA, McGlashan TH, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, Woods SW, Bearden CE, Mathalon DH, Addington J. The role of a family history of psychosis for youth at clinical high risk of psychosis. Early Intervention in Psychiatry. PMID 28792113 DOI: 10.1111/Eip.12471 |
0.393 |
|
| 2017 |
Marshall C, Lu Y, Lyngberg K, Deighton S, Cadenhead KS, Cannon TD, Cornblatt BA, McGlashan TH, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, Woods SW, Bearden CE, Mathalon D, et al. Changes in symptom content from a clinical high-risk state to conversion to psychosis. Early Intervention in Psychiatry. PMID 28771938 DOI: 10.1111/Eip.12473 |
0.399 |
|
| 2017 |
Kline ER, Seidman LJ, Cornblatt BA, Woodberry KA, Bryant C, Bearden CE, Cadenhead KS, Cannon TD, Mathalon DH, McGlashan TH, Perkins DO, Tsuang MT, Walker EF, Woods SW, Addington J. Depression and clinical high-risk states: Baseline presentation of depressed vs. non-depressed participants in the NAPLS-2 cohort. Schizophrenia Research. PMID 28578922 DOI: 10.1016/J.Schres.2017.05.032 |
0.304 |
|
| 2017 |
Velthorst E, Zinberg J, Addington J, Cadenhead KS, Cannon TD, Carrión RE, Auther A, Cornblatt BA, McGlashan TH, Mathalon DH, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, Woods SW, et al. Potentially important periods of change in the development of social and role functioning in youth at clinical high risk for psychosis. Development and Psychopathology. 1-9. PMID 28420458 DOI: 10.1017/S0954579417000451 |
0.333 |
|
| 2017 |
Blanchard JJ, Bradshaw KR, Garcia CP, Nasrallah HA, Harvey PD, Casey D, Csoboth CT, Hudson JI, Julian L, Lentz E, Nuechterlein KH, Perkins DO, Skale TG, Snowden LR, Tandon R, et al. Examining the reliability and validity of the Clinical Assessment Interview for Negative Symptoms within the Management of Schizophrenia in Clinical Practice (MOSAIC) multisite national study. Schizophrenia Research. PMID 28087270 DOI: 10.1016/J.Schres.2017.01.011 |
0.432 |
|
| 2017 |
Charney AW, Ruderfer DM, Stahl EA, Moran JL, Chambert K, Belliveau RA, Forty L, Gordon-Smith K, Di Florio A, Lee PH, Bromet EJ, Buckley PF, Escamilla MA, Fanous AH, Fochtmann LJ, ... ... Perkins DO, et al. Evidence for genetic heterogeneity between clinical subtypes of bipolar disorder. Translational Psychiatry. 7: e993. PMID 28072414 DOI: 10.1038/Tp.2016.242 |
0.34 |
|
| 2017 |
Devoe D, Cadenhead K, Cannon T, Cornblatt B, McGlashan T, Perkins D, Seidman LJ, Tsuang M, Walker E, Woods S, Bearden C, Mathalon D, Addington J. SU127. Negative Symptoms in Youth at Clinical High Risk of Psychosis Schizophrenia Bulletin. 43: S207-S207. DOI: 10.1093/Schbul/Sbx024.123 |
0.418 |
|
| 2017 |
Mirzakhanian H, Sanchez S, Addington J, Bearden C, Cannon T, Cornblatt B, Mathalon D, McGlashan T, Perkins D, Seidman LJ, Tsuang M, Walker E, Woods SW, Cadenhead K. 209. Risk of Violence in Attenuated Psychosis Symptoms Syndrome and its Relationship With Symptomology Schizophrenia Bulletin. 43: S106-S107. DOI: 10.1093/Schbul/Sbx021.287 |
0.413 |
|
| 2017 |
Davidson C, Piskulic D, Addington J, Cadenhead K, Cannon T, Cornblatt B, McGlashan T, Perkins D, Seidman LJ, Tsuang M, Walker E, Bearden C, Mathalon D, Woods S, Johannesen J. 192. Different Age-Related Trajectories of Social Cognition in Youths at Clinical High Risk of Psychosis Schizophrenia Bulletin. 43: S100-S101. DOI: 10.1093/Schbul/Sbx021.270 |
0.357 |
|
| 2017 |
Burrell H, Lawson M, Addington J, Bearden C, Cadenhead K, Cannon T, Cornblatt B, Jeffries C, Mathalon D, McGlashan T, Seidman L, Tsuang M, Walker E, Woods S, Perkins D. 155. Tobacco Use and Psychosis Risk in Persons at Clinical High Risk Schizophrenia Bulletin. 43: S80-S80. DOI: 10.1093/Schbul/Sbx021.213 |
0.359 |
|
| 2017 |
Woods S, Saksa J, Compton M, Daley M, Rajarethinam R, Graham K, Breitborde N, Cahill J, Srihari V, Perkins D, Bearden C, Cannon T, Walker E, McGlashan T. 112. Effects of Ziprasidone Versus Placebo in Patients at Clinical High Risk for Psychosis Schizophrenia Bulletin. 43: S58-S58. DOI: 10.1093/Schbul/Sbx021.150 |
0.38 |
|
| 2017 |
Auther A, Carrion R, McLaughlin D, Addington J, Bearden C, Cadenhead K, Cannon T, Mathalon D, McGlashan TH, Perkins D, Seidman LJ, Tsuang M, Walker E, Woods S, Cornblatt B. 100. Converging Evidence for Social Functioning Deficits as a Neurodevelopmental Risk Factor in High-Risk Youth Schizophrenia Bulletin. 43: S53-S53. DOI: 10.1093/Schbul/Sbx021.138 |
0.347 |
|
| 2017 |
Hamilton H, Bachman P, Belger A, Carrion R, Duncan E, Johannesen J, Light G, Niznikiewicz M, Roach B, Addington J, Bearden C, Cadenhead K, Cannon T, Cornblatt B, McGlashan T, ... Perkins D, et al. 80. Auditory Target Processing Deficits in Individuals at Clinical High Risk for Psychosis Schizophrenia Bulletin. 43: S45-S45. DOI: 10.1093/Schbul/Sbx021.119 |
0.367 |
|
| 2017 |
Jeffries C, Perkins D, Addington J, Bearden C, Cadenhead K, Cannon T, Cornblatt B, Mathalon D, McGlashan T, Seidman LJ, Tsuang M, Walker E, Woods S. 59.4 Networks of Blood Analytes are Collectively Informative of Risk of Conversion to Schizophrenia Schizophrenia Bulletin. 43: S33-S33. DOI: 10.1093/Schbul/Sbx021.086 |
0.364 |
|
| 2017 |
Velthorst E, Bearden C, Addington J, Cadenhead K, Cannon T, Carrion R, Auther A, Cornblatt B, McGlashan T, Mathalon D, Perkins D, Tsuang M, Walker E, Woods S, Meyer E, et al. 42. Heterogeneity of Neuropsychological Profiles in the Prodrome to Psychosis: An Examination of the Association Between Cognition and Clinical Outcomes in NAPLS-1 Schizophrenia Bulletin. 43: S23-S24. DOI: 10.1093/Schbul/Sbx021.061 |
0.324 |
|
| 2017 |
Cadenhead K, Addington J, Cannon T, Cornblatt B, Mathalon D, McGlashan T, Perkins D, Seidman LJ, Tsuang M, Walker E, Woods S. 23. Omega-3 Fatty Acid Versus Placebo in a Clinical High-Risk Sample From the North American Prodrome Longitudinal Studies (NAPLS) Consortium Schizophrenia Bulletin. 43: S16-S16. DOI: 10.1093/Schbul/Sbx021.042 |
0.312 |
|
| 2017 |
Kelsven S, Addington J, Bearden C, Cannon T, Cornblatt B, Mathalon D, McGlashan T, Perkins D, Seidman L, Walker E, Woods S, Cadenhead K. 20. Metabolic Abnormalities and Omega-3 Fatty Acids in Latinos at Clinical High Risk for Psychosis Schizophrenia Bulletin. 43: S14-S15. DOI: 10.1093/Schbul/Sbx021.039 |
0.315 |
|
| 2016 |
Seidman LJ, Shapiro DI, Stone WS, Woodberry KA, Ronzio A, Cornblatt BA, Addington J, Bearden CE, Cadenhead KS, Cannon TD, Mathalon DH, McGlashan TH, Perkins DO, Tsuang MT, Walker EF, et al. Association of Neurocognition With Transition to Psychosis: Baseline Functioning in the Second Phase of the North American Prodrome Longitudinal Study. Jama Psychiatry. PMID 27806157 DOI: 10.1001/Jamapsychiatry.2016.2479 |
0.456 |
|
| 2016 |
Addington J, Liu L, Perkins DO, Carrion RE, Keefe RS, Woods SW. The Role of Cognition and Social Functioning as Predictors in the Transition to Psychosis for Youth With Attenuated Psychotic Symptoms. Schizophrenia Bulletin. PMID 27798225 DOI: 10.1093/Schbul/Sbw152 |
0.352 |
|
| 2016 |
Woodberry KA, Seidman LJ, Bryant C, Addington J, Bearden CE, S Cadenhead K, Cannon TD, Cornblatt BA, McGlashan TH, Mathalon DH, Perkins DO, Tsuang MT, Walker EF, Woods SW. Treatment Precedes Positive Symptoms in North American Adolescent and Young Adult Clinical High Risk Cohort. Journal of Clinical Child and Adolescent Psychology : the Official Journal For the Society of Clinical Child and Adolescent Psychology, American Psychological Association, Division 53. 1-10. PMID 27705009 DOI: 10.1080/15374416.2016.1212361 |
0.426 |
|
| 2016 |
Marshall C, Deighton S, Cadenhead KS, Cannon TD, Cornblatt BA, McGlashan TH, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, Woods SW, Bearden CE, Mathalon D, Addington J. The Violent Content in Attenuated Psychotic Symptoms. Psychiatry Research. 242: 61-66. PMID 27259137 DOI: 10.1016/J.Psychres.2016.05.005 |
0.362 |
|
| 2016 |
McLaughlin D, Carrión RE, Auther AM, Olvet DM, Addington J, Bearden CE, Cadenhead KS, Cannon TD, Heinssen RK, Mathalon DH, McGlashan TH, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, et al. Functional Capacity Assessed by the Map Task in Individuals at Clinical High-Risk for Psychosis. Schizophrenia Bulletin. PMID 27105902 DOI: 10.1093/Schbul/Sbw039 |
0.374 |
|
| 2016 |
Moskow DM, Addington J, Bearden CE, Cadenhead KS, Cornblatt BA, Heinssen R, Mathalon DH, McGlashan TH, Perkins DO, Seidman LJ, Tsuang MT, Cannon TD, Woods SW, Walker EF. The relations of age and pubertal development with cortisol and daily stress in youth at clinical risk for psychosis. Schizophrenia Research. PMID 26905038 DOI: 10.1016/J.Schres.2016.02.002 |
0.305 |
|
| 2016 |
Stowkowy J, Liu L, Cadenhead KS, Cannon TD, Cornblatt BA, McGlashan TH, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, Woods SW, Bearden CE, Mathalon DH, Addington J. Early traumatic experiences, perceived discrimination and conversion to psychosis in those at clinical high risk for psychosis. Social Psychiatry and Psychiatric Epidemiology. PMID 26851943 DOI: 10.1007/S00127-016-1182-Y |
0.41 |
|
| 2015 |
Hart SJ, Shaffer JJ, Bizzell J, Weber M, McMahon MA, Gu H, Perkins DO, Belger A. Measurement of Fronto-limbic Activity Using an Emotional Oddball Task in Children with Familial High Risk for Schizophrenia. Journal of Visualized Experiments : Jove. PMID 26650392 DOI: 10.3791/51484 |
0.327 |
|
| 2015 |
Fusar-Poli P, Schultze-Lutter F, Cappucciati M, Rutigliano G, Bonoldi I, Stahl D, Borgwardt S, Riecher-Rössler A, Addington J, Perkins DO, Woods SW, McGlashan T, Lee J, Klosterkötter J, Yung AR, et al. The Dark Side of the Moon: Meta-analytical Impact of Recruitment Strategies on Risk Enrichment in the Clinical High Risk State for Psychosis. Schizophrenia Bulletin. PMID 26591006 DOI: 10.1093/Schbul/Sbv162 |
0.371 |
|
| 2015 |
Lyngberg K, Buchy L, Liu L, Perkins D, Woods S, Addington J. Patterns of premorbid functioning in individuals at clinical high risk of psychosis. Schizophrenia Research. PMID 26589390 DOI: 10.1016/J.Schres.2015.11.004 |
0.418 |
|
| 2015 |
Buchy L, Cannon TD, Anticevic A, Lyngberg K, Cadenhead KS, Cornblatt BA, McGlashan TH, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, Woods SW, Bearden CE, Mathalon DH, Addington J. Evaluating the impact of cannabis use on thalamic connectivity in youth at clinical high risk of psychosis. Bmc Psychiatry. 15: 276. PMID 26553191 DOI: 10.1186/S12888-015-0656-X |
0.343 |
|
| 2015 |
Fusar-Poli P, Cappucciati M, Rutigliano G, Schultze-Lutter F, Bonoldi I, Borgwardt S, Riecher-Rössler A, Addington J, Perkins D, Woods SW, McGlashan TH, Lee J, Klosterkötter J, Yung AR, McGuire P. At risk or not at risk? A meta-analysis of the prognostic accuracy of psychometric interviews for psychosis prediction. World Psychiatry : Official Journal of the World Psychiatric Association (Wpa). 14: 322-32. PMID 26407788 DOI: 10.1002/Wps.20250 |
0.372 |
|
| 2015 |
Webb JR, Addington J, Perkins DO, Bearden CE, Cadenhead KS, Cannon TD, Cornblatt BA, Heinssen RK, Seidman LJ, Tarbox SI, Tsuang MT, Walker EF, McGlashan TH, Woods SW. Specificity of Incident Diagnostic Outcomes in Patients at Clinical High Risk for Psychosis. Schizophrenia Bulletin. 41: 1066-75. PMID 26272875 DOI: 10.1093/Schbul/Sbv091 |
0.34 |
|
| 2015 |
Anticevic A, Haut K, Murray JD, Repovs G, Yang GJ, Diehl C, McEwen SC, Bearden CE, Addington J, Goodyear B, Cadenhead KS, Mirzakhanian H, Cornblatt BA, Olvet D, Mathalon DH, ... ... Perkins DO, et al. Association of Thalamic Dysconnectivity and Conversion to Psychosis in Youth and Young Adults at Elevated Clinical Risk. Jama Psychiatry. PMID 26267151 DOI: 10.1001/Jamapsychiatry.2015.0566 |
0.462 |
|
| 2015 |
Nasrallah HA, Harvey PD, Casey D, Csoboth CT, Hudson JI, Julian L, Lentz E, Nuechterlein KH, Perkins DO, Kotowsky N, Skale TG, Snowden LR, Tandon R, Tek C, Velligan D, et al. The Management of Schizophrenia in Clinical Practice (MOSAIC) Registry: A focus on patients, caregivers, illness severity, functional status, disease burden and healthcare utilization. Schizophrenia Research. PMID 26027848 DOI: 10.1016/J.Schres.2015.04.031 |
0.407 |
|
| 2015 |
Chung Y, Jacobson A, He G, van Erp TG, McEwen S, Addington J, Bearden CE, Cadenhead K, Cornblatt B, Mathalon DH, McGlashan T, Perkins D, Seidman LJ, Tsuang M, Walker E, et al. Prodromal Symptom Severity Predicts Accelerated Gray Matter Reduction and Third Ventricle Expansion Among Clinically High Risk Youth Developing Psychotic Disorders. Molecular Neuropsychiatry. 1: 13-22. PMID 26005673 DOI: 10.1159/000371887 |
0.314 |
|
| 2015 |
Addington J, Liu L, Buchy L, Cadenhead KS, Cannon TD, Cornblatt BA, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, Woods SW, Bearden CE, Mathalon DH, McGlashan TH. North American Prodrome Longitudinal Study (NAPLS 2): The Prodromal Symptoms. The Journal of Nervous and Mental Disease. 203: 328-35. PMID 25919383 DOI: 10.1097/Nmd.0000000000000290 |
0.376 |
|
| 2015 |
Stowkowy J, Liu L, Cadenhead KS, Cannon TD, Cornblatt BA, McGlashan TH, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, Woods SW, Bearden CE, Mathalon DH, Heinssen R, Addington J. Core Schemas in Youth at Clinical High Risk for Psychosis. Behavioural and Cognitive Psychotherapy. 1-11. PMID 25896713 DOI: 10.1017/S1352465815000144 |
0.366 |
|
| 2015 |
Buchy L, Cadenhead KS, Cannon TD, Cornblatt BA, McGlashan TH, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, Woods SW, Heinssen R, Bearden CE, Mathalon D, Addington J. Substance use in individuals at clinical high risk of psychosis. Psychological Medicine. 45: 2275-84. PMID 25727300 DOI: 10.1017/S0033291715000227 |
0.359 |
|
| 2015 |
Auther AM, Cadenhead KS, Carrión RE, Addington J, Bearden CE, Cannon TD, McGlashan TH, Perkins DO, Seidman L, Tsuang M, Walker EF, Woods SW, Cornblatt BA. Alcohol confounds relationship between cannabis misuse and psychosis conversion in a high-risk sample. Acta Psychiatrica Scandinavica. 132: 60-8. PMID 25572323 DOI: 10.1111/Acps.12382 |
0.349 |
|
| 2015 |
Cannon TD, Chung Y, He G, Sun D, Jacobson A, van Erp TG, McEwen S, Addington J, Bearden CE, Cadenhead K, Cornblatt B, Mathalon DH, McGlashan T, Perkins D, Jeffries C, et al. Progressive reduction in cortical thickness as psychosis develops: a multisite longitudinal neuroimaging study of youth at elevated clinical risk. Biological Psychiatry. 77: 147-57. PMID 25034946 DOI: 10.1016/J.Biopsych.2014.05.023 |
0.35 |
|
| 2014 |
Callaway DA, Perkins DO, Woods SW, Liu L, Addington J. Movement abnormalities predict transitioning to psychosis in individuals at clinical high risk for psychosis. Schizophrenia Research. 159: 263-6. PMID 25311779 DOI: 10.1016/J.Schres.2014.09.031 |
0.365 |
|
| 2014 |
Marshall C, Denny E, Cadenhead KS, Cannon TD, Cornblatt BA, McGlashan TH, Perkins DO, Seidman LJ, Tsuang MT, Woods SW, Walker E, Addington J. The content of attenuated psychotic symptoms in those at clinical high risk for psychosis. Psychiatry Research. 219: 506-12. PMID 25048759 DOI: 10.1016/J.Psychres.2014.06.023 |
0.387 |
|
| 2014 |
Stowkowy J, Perkins DO, Woods SW, Nyman K, Addington J. Personal Beliefs about Experiences in those at Clinical High Risk for Psychosis. Behavioural and Cognitive Psychotherapy. 1-7. PMID 24949991 DOI: 10.1017/S1352465814000307 |
0.425 |
|
| 2014 |
Kelly AC, Sheitman BB, Hamer RM, Rhyne DC, Reed RM, Graham KA, Rau SW, Gilmore JH, Perkins DO, Peebles SS, VanderZwaag CJ, Jarskog LF. A naturalistic comparison of the long-term metabolic adverse effects of clozapine versus other antipsychotics for patients with psychotic illnesses. Journal of Clinical Psychopharmacology. 34: 441-5. PMID 24943389 DOI: 10.1097/Jcp.0000000000000159 |
0.33 |
|
| 2014 |
Buchy L, Perkins D, Woods SW, Liu L, Addington J. Impact of substance use on conversion to psychosis in youth at clinical high risk of psychosis. Schizophrenia Research. 156: 277-80. PMID 24837058 DOI: 10.1016/J.Schres.2014.04.021 |
0.339 |
|
| 2014 |
Yong E, Barbato M, Penn DL, Keefe RS, Woods SW, Perkins DO, Addington J. Exploratory analysis of social cognition and neurocognition in individuals at clinical high risk for psychosis. Psychiatry Research. 218: 39-43. PMID 24755041 DOI: 10.1016/J.Psychres.2014.04.003 |
0.353 |
|
| 2014 |
Graham KA, Keefe RS, Lieberman JA, Calikoglu AS, Lansing KM, Perkins DO. Relationship of low vitamin D status with positive, negative and cognitive symptom domains in people with first-episode schizophrenia. Early Intervention in Psychiatry. PMID 24612563 DOI: 10.1111/Eip.12122 |
0.363 |
|
| 2014 |
Alderman T, Addington J, Bearden C, Cannon TD, Cornblatt BA, McGlashan TH, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, Woods SW, Cadenhead KS. Negative symptoms and impaired social functioning predict later psychosis in Latino youth at clinical high risk in the North American prodromal longitudinal studies consortium. Early Intervention in Psychiatry. PMID 24576057 DOI: 10.1111/Eip.12128 |
0.31 |
|
| 2014 |
Meyer EC, Carrión RE, Cornblatt BA, Addington J, Cadenhead KS, Cannon TD, McGlashan TH, Perkins DO, Tsuang MT, Walker EF, Woods SW, Heinssen R, Seidman LJ. The relationship of neurocognition and negative symptoms to social and role functioning over time in individuals at clinical high risk in the first phase of the North American Prodrome Longitudinal Study. Schizophrenia Bulletin. 40: 1452-61. PMID 24550526 DOI: 10.1093/Schbul/Sbt235 |
0.436 |
|
| 2014 |
Tarbox SI, Addington J, Cadenhead KS, Cannon TD, Cornblatt BA, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, Heinssen R, McGlashan TH, Woods SW. Functional development in clinical high risk youth: prediction of schizophrenia versus other psychotic disorders. Psychiatry Research. 215: 52-60. PMID 24200216 DOI: 10.1016/J.Psychres.2013.10.006 |
0.441 |
|
| 2014 |
Barbato M, Penn DL, Perkins DO, Woods SW, Liu L, Addington J. Metacognitive functioning in individuals at clinical high risk for psychosis. Behavioural and Cognitive Psychotherapy. 42: 526-34. PMID 23517866 DOI: 10.1017/S1352465813000167 |
0.444 |
|
| 2014 |
Cadenhead K, Addington J, Bearden CE, Cannon T, McGlashan T, Mathalon D, Perkins D, Seidman LI, Tsuang M, Walker E, Woods S. Poster #T38 PREDICTION OF SYMPTOM OUTCOME IN CLINICAL HIGH RISK SUBJECTS USING THE ACOUSTIC STARTLE PARADIGM Schizophrenia Research. 153: S302-S303. DOI: 10.1016/S0920-9964(14)70855-2 |
0.363 |
|
| 2013 |
Tarbox SI, Addington J, Cadenhead KS, Cannon TD, Cornblatt BA, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, Heinssen R, McGlashan TH, Woods SW. Premorbid functional development and conversion to psychosis in clinical high-risk youths. Development and Psychopathology. 25: 1171-86. PMID 24229556 DOI: 10.1017/S0954579413000448 |
0.301 |
|
| 2013 |
Healey KM, Penn DL, Perkins D, Woods SW, Addington J. Theory of mind and social judgments in people at clinical high risk of psychosis. Schizophrenia Research. 150: 498-504. PMID 24055202 DOI: 10.1016/J.Schres.2013.08.038 |
0.351 |
|
| 2013 |
Barbato M, Liu L, Penn DL, Keefe RS, Perkins DO, Woods SW, Addington J. Social cognition as a mediator between neurocognition and functional outcome in individuals at clinical high risk for psychosis. Schizophrenia Research. 150: 542-6. PMID 24012459 DOI: 10.1016/J.Schres.2013.08.015 |
0.324 |
|
| 2013 |
Walker EF, Trotman HD, Pearce BD, Addington J, Cadenhead KS, Cornblatt BA, Heinssen R, Mathalon DH, Perkins DO, Seidman LJ, Tsuang MT, Cannon TD, McGlashan TH, Woods SW. Cortisol levels and risk for psychosis: initial findings from the North American prodrome longitudinal study. Biological Psychiatry. 74: 410-7. PMID 23562006 DOI: 10.1016/J.Biopsych.2013.02.016 |
0.403 |
|
| 2013 |
Hart SJ, Bizzell J, McMahon MA, Gu H, Perkins DO, Belger A. Altered fronto-limbic activity in children and adolescents with familial high risk for schizophrenia. Psychiatry Research. 212: 19-27. PMID 23482245 DOI: 10.1016/J.Pscychresns.2012.12.003 |
0.366 |
|
| 2013 |
Addington J, Stowkowy J, Cadenhead KS, Cornblatt BA, McGlashan TH, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, Woods SW, Cannon TD. Early traumatic experiences in those at clinical high risk for psychosis. Early Intervention in Psychiatry. 7: 300-5. PMID 23343384 DOI: 10.1111/Eip.12020 |
0.386 |
|
| 2013 |
Walder DJ, Holtzman CW, Addington J, Cadenhead K, Tsuang M, Cornblatt B, Cannon TD, McGlashan TH, Woods SW, Perkins DO, Seidman LJ, Heinssen R, Walker EF. Sexual dimorphisms and prediction of conversion in the NAPLS psychosis prodrome. Schizophrenia Research. 144: 43-50. PMID 23340377 DOI: 10.1016/J.Schres.2012.11.039 |
0.365 |
|
| 2013 |
Barbato M, Colijn MA, Keefe RS, Perkins DO, Woods SW, Hawkins KA, Christensen BK, Addington J. The course of cognitive functioning over six months in individuals at clinical high risk for psychosis. Psychiatry Research. 206: 195-9. PMID 23159196 DOI: 10.1016/J.Psychres.2012.10.013 |
0.334 |
|
| 2012 |
Dougherty MK, Gu H, Bizzell J, Ramsey S, Gerig G, Perkins DO, Belger A. Differences in subcortical structures in young adolescents at familial risk for schizophrenia: a preliminary study. Psychiatry Research. 204: 68-74. PMID 23146250 DOI: 10.1016/J.Pscychresns.2012.04.016 |
0.431 |
|
| 2012 |
Addington J, Cadenhead KS, Cornblatt BA, Mathalon DH, McGlashan TH, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, Woods SW, Addington JA, Cannon TD. North American Prodrome Longitudinal Study (NAPLS 2): overview and recruitment. Schizophrenia Research. 142: 77-82. PMID 23043872 DOI: 10.1016/J.Schres.2012.09.012 |
0.338 |
|
| 2012 |
Addington J, Piskulic D, Perkins D, Woods SW, Liu L, Penn DL. Affect recognition in people at clinical high risk of psychosis. Schizophrenia Research. 140: 87-92. PMID 22763425 DOI: 10.1016/J.Schres.2012.06.012 |
0.439 |
|
| 2012 |
Uzenoff SR, Penn DL, Graham KA, Saade S, Smith BB, Perkins DO. Evaluation of a multi-element treatment center for early psychosis in the United States. Social Psychiatry and Psychiatric Epidemiology. 47: 1607-15. PMID 22278376 DOI: 10.1007/S00127-011-0467-4 |
0.358 |
|
| 2012 |
Cornblatt BA, Carrión RE, Addington J, Seidman L, Walker EF, Cannon TD, Cadenhead KS, McGlashan TH, Perkins DO, Tsuang MT, Woods SW, Heinssen R, Lencz T. Risk factors for psychosis: impaired social and role functioning. Schizophrenia Bulletin. 38: 1247-57. PMID 22080497 DOI: 10.1093/Schbul/Sbr136 |
0.413 |
|
| 2012 |
Gee DG, Karlsgodt KH, van Erp TG, Bearden CE, Lieberman MD, Belger A, Perkins DO, Olvet DM, Cornblatt BA, Constable T, Woods SW, Addington J, Cadenhead KS, McGlashan TH, Seidman LJ, et al. Altered age-related trajectories of amygdala-prefrontal circuitry in adolescents at clinical high risk for psychosis: a preliminary study. Schizophrenia Research. 134: 1-9. PMID 22056201 DOI: 10.1016/J.Schres.2011.10.005 |
0.346 |
|
| 2012 |
Aberg K, Adkins DE, Liu Y, McClay JL, Bukszár J, Jia P, Zhao Z, Perkins D, Stroup TS, Lieberman JA, Sullivan PF, van den Oord EJ. Genome-wide association study of antipsychotic-induced QTc interval prolongation. The Pharmacogenomics Journal. 12: 165-72. PMID 20921969 DOI: 10.1038/Tpj.2010.76 |
0.313 |
|
| 2012 |
Colijn MA, Barbato M, Keefe RS, Perkins DO, Woods SW, Addington J. Poster #143 AT RISK FOR PSYCHOSIS: THE ROLE OF COGNITION Schizophrenia Research. 136: S237. DOI: 10.1016/S0920-9964(12)70715-6 |
0.328 |
|
| 2012 |
Piskulic D, Penn D, Perkins D, Woods S, Liu L, Addington J. Poster #162 AFFECT RECOGNITION IN PEOPLE AT CLINICAL HIGH RISK OF PSYCHOSIS Schizophrenia Research. 136: S149-S150. DOI: 10.1016/S0920-9964(12)70476-0 |
0.382 |
|
| 2011 |
Donkers FC, Schwikert SR, Evans AM, Cleary KM, Perkins DO, Belger A. Impaired neural synchrony in the theta frequency range in adolescents at familial risk for schizophrenia. Frontiers in Psychiatry. 2: 51. PMID 21991257 DOI: 10.3389/Fpsyt.2011.00051 |
0.397 |
|
| 2011 |
Stroup TS, McEvoy JP, Ring KD, Hamer RH, LaVange LM, Swartz MS, Rosenheck RA, Perkins DO, Nussbaum AM, Lieberman JA. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). The American Journal of Psychiatry. 168: 947-56. PMID 21768610 DOI: 10.1176/Appi.Ajp.2011.10111609 |
0.324 |
|
| 2011 |
Addington J, Cornblatt BA, Cadenhead KS, Cannon TD, McGlashan TH, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, Woods SW, Heinssen R. At clinical high risk for psychosis: outcome for nonconverters. The American Journal of Psychiatry. 168: 800-5. PMID 21498462 DOI: 10.1176/Appi.Ajp.2011.10081191 |
0.445 |
|
| 2011 |
McClay JL, Adkins DE, Aberg K, Bukszár J, Khachane AN, Keefe RS, Perkins DO, McEvoy JP, Stroup TS, Vann RE, Beardsley PM, Lieberman JA, Sullivan PF, van den Oord EJ. Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 36: 616-26. PMID 21107309 DOI: 10.1038/Npp.2010.193 |
0.344 |
|
| 2011 |
Penn DL, Uzenoff SR, Perkins D, Mueser KT, Hamer R, Waldheter E, Saade S, Cook L. A pilot investigation of the Graduated Recovery Intervention Program (GRIP) for first episode psychosis. Schizophrenia Research. 125: 247-56. PMID 20817484 DOI: 10.1016/J.Schres.2010.08.006 |
0.323 |
|
| 2011 |
Adkins DE, Aberg K, McClay JL, Bukszár J, Zhao Z, Jia P, Stroup TS, Perkins D, McEvoy JP, Lieberman JA, Sullivan PF, van den Oord EJ. Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs. Molecular Psychiatry. 16: 321-32. PMID 20195266 DOI: 10.1038/Mp.2010.14 |
0.34 |
|
| 2011 |
McClay JL, Adkins DE, Aberg K, Stroup S, Perkins DO, Vladimirov VI, Lieberman JA, Sullivan PF, van den Oord EJ. Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics. Molecular Psychiatry. 16: 76-85. PMID 19721433 DOI: 10.1038/Mp.2009.89 |
0.384 |
|
| 2011 |
Jeffries CD, Perkins DO, Sullivan P, Guan X. Massively parallel sequencing from prefrontal cortex reveals multiple novel small RNAs and microRNAs associated with schizophrenia F1000research. 2. DOI: 10.7490/F1000Research.1382.1 |
0.308 |
|
| 2010 |
Cadenhead KS, Addington J, Cannon T, Cornblatt B, McGlashan T, Perkins D, Seidman L, Tsuang M, Walker E, Woods S, Heinssen R. Treatment history in the psychosis prodrome: characteristics of the North American Prodrome Longitudinal Study Cohort. Early Intervention in Psychiatry. 4: 220-6. PMID 20712727 DOI: 10.1111/J.1751-7893.2010.00183.X |
0.423 |
|
| 2010 |
Gibson CM, Penn DL, Prinstein MJ, Perkins DO, Belger A. Social skill and social cognition in adolescents at genetic risk for psychosis. Schizophrenia Research. 122: 179-84. PMID 20570111 DOI: 10.1016/J.Schres.2010.04.018 |
0.333 |
|
| 2010 |
Uzenoff SR, Brewer KC, Perkins DO, Johnson DP, Mueser KT, Penn DL. Psychological well-being among individuals with first-episode psychosis. Early Intervention in Psychiatry. 4: 174-81. PMID 20536974 DOI: 10.1111/J.1751-7893.2010.00178.X |
0.385 |
|
| 2010 |
Seidman LJ, Giuliano AJ, Meyer EC, Addington J, Cadenhead KS, Cannon TD, McGlashan TH, Perkins DO, Tsuang MT, Walker EF, Woods SW, Bearden CE, Christensen BK, Hawkins K, Heaton R, et al. Neuropsychology of the prodrome to psychosis in the NAPLS consortium: relationship to family history and conversion to psychosis. Archives of General Psychiatry. 67: 578-88. PMID 20530007 DOI: 10.1016/J.Schres.2010.02.210 |
0.442 |
|
| 2010 |
Konneker TI, Crowley JJ, Quackenbush CR, Keefe RS, Perkins DO, Stroup TS, Lieberman JA, van den Oord E, Sullivan PF. No association of the serotonin transporter polymorphisms 5-HTTLPR and RS25531 with schizophrenia or neurocognition. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics. 153: 1115-7. PMID 20468059 DOI: 10.1002/Ajmg.B.31077 |
0.335 |
|
| 2010 |
Holtzman CW, Larson MK, Addington J, Cadenhead K, Cannon TD, Cornblatt B, Heinssen R, McGlashan T, Perkins D, Seidman LJ, Tsuang M, Woods SW, Walker EF. SEX DIFFERENCES IN SYMPTOM PRESENTATION IN INDIVIDUALS AT RISK FOR PSYCHOSIS Schizophrenia Research. 117: 304-305. DOI: 10.1016/J.Schres.2010.02.508 |
0.388 |
|
| 2010 |
Addington J, Cornblatt B, Cadenhead K, Cannon T, Heinssen R, McGlashan T, Perkins D, Tsuang M, Walker E, Woods S, Seidman L. CLINICAL HIGH RISK FOR PSYCHOSIS: THE RISK OF FALSE POSITIVE Schizophrenia Research. 117: 279. DOI: 10.1016/J.Schres.2010.02.452 |
0.365 |
|
| 2009 |
McCarthy SE, Makarov V, Kirov G, Addington AM, McClellan J, Yoon S, Perkins DO, Dickel DE, Kusenda M, Krastoshevsky O, Krause V, Kumar RA, Grozeva D, Malhotra D, Walsh T, et al. Microduplications of 16p11.2 are associated with schizophrenia. Nature Genetics. 41: 1223-7. PMID 19855392 DOI: 10.1038/Ng.474 |
0.341 |
|
| 2009 |
Penn DL, Keefe RS, Davis SM, Meyer PS, Perkins DO, Losardo D, Lieberman JA. The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial. Schizophrenia Research. 115: 17-23. PMID 19766459 DOI: 10.1016/J.Schres.2009.08.016 |
0.324 |
|
| 2009 |
Woods SW, Addington J, Cadenhead KS, Cannon TD, Cornblatt BA, Heinssen R, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, McGlashan TH. Validity of the prodromal risk syndrome for first psychosis: findings from the North American Prodrome Longitudinal Study. Schizophrenia Bulletin. 35: 894-908. PMID 19386578 DOI: 10.1093/Schbul/Sbp027 |
0.381 |
|
| 2009 |
Thompson PM, Bartzokis G, Hayashi KM, Klunder AD, Lu PH, Edwards N, Hong MS, Yu M, Geaga JA, Toga AW, Charles C, Perkins DO, McEvoy J, Hamer RM, Tohen M, et al. Time-lapse mapping of cortical changes in schizophrenia with different treatments. Cerebral Cortex (New York, N.Y. : 1991). 19: 1107-23. PMID 18842668 DOI: 10.1093/Cercor/Bhn152 |
0.368 |
|
| 2009 |
Sullivan PF, Lin D, Tzeng J, van den Oord E, Perkins D, Stroup TS, Wagner M, Lee S, Wright FA, Zou F, Liu W, Downing AM, Lieberman J, Close SL. Erratum: Genomewide association for schizophrenia in the CATIE study: results of stage 1 Molecular Psychiatry. 14: 1144-1144. DOI: 10.1038/Mp.2008.74 |
0.37 |
|
| 2008 |
Hawkins KA, Keefe RS, Christensen BK, Addington J, Woods SW, Callahan J, Zipursky RB, Perkins DO, Tohen M, Breier A, McGlashan TH. Neuropsychological course in the prodrome and first episode of psychosis: findings from the PRIME North America Double Blind Treatment Study. Schizophrenia Research. 105: 1-9. PMID 18774696 DOI: 10.1016/J.Schres.2008.07.008 |
0.438 |
|
| 2008 |
Uzenoff SR, Perkins DO, Hamer RM, Wiesen CA, Penn DL. A preliminary trial of adherence-coping-education (ACE) therapy for early psychosis. The Journal of Nervous and Mental Disease. 196: 572-5. PMID 18626299 DOI: 10.1097/Nmd.0B013E31817D01A5 |
0.323 |
|
| 2008 |
Waldheter EJ, Penn DL, Perkins DO, Mueser KT, Owens LW, Cook E. The graduated recovery intervention program for first episode psychosis: treatment development and preliminary data. Community Mental Health Journal. 44: 443-55. PMID 18516680 DOI: 10.1007/S10597-008-9147-6 |
0.307 |
|
| 2008 |
Lieberman JA, Drake RE, Sederer LI, Belger A, Keefe R, Perkins D, Stroup S. Science and recovery in schizophrenia. Psychiatric Services (Washington, D.C.). 59: 487-96. PMID 18451003 DOI: 10.1176/Ps.2008.59.5.487 |
0.407 |
|
| 2008 |
Sullivan PF, Lin D, Tzeng JY, van den Oord E, Perkins D, Stroup TS, Wagner M, Lee S, Wright FA, Zou F, Liu W, Downing AM, Lieberman J, Close SL. Genomewide association for schizophrenia in the CATIE study: results of stage 1. Molecular Psychiatry. 13: 570-84. PMID 18347602 DOI: 10.1038/Mp.2008.25 |
0.362 |
|
| 2008 |
Perkins DO, Gu H, Weiden PJ, McEvoy JP, Hamer RM, Lieberman JA. Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. The Journal of Clinical Psychiatry. 69: 106-13. PMID 18312044 DOI: 10.4088/Jcp.V69N0114 |
0.327 |
|
| 2008 |
Crowley JJ, Keefe RS, Perkins DO, Stroup TS, Lieberman JA, Sullivan PF. The neuregulin 1 promoter polymorphism rs6994992 is not associated with chronic schizophrenia or neurocognition. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics. 147: 1298-300. PMID 18286587 DOI: 10.1002/Ajmg.B.30727 |
0.355 |
|
| 2008 |
Hill SK, Sweeney JA, Hamer RM, Keefe RS, Perkins DO, Gu H, McEvoy JP, Lieberman JA. Efficiency of the CATIE and BACS neuropsychological batteries in assessing cognitive effects of antipsychotic treatments in schizophrenia. Journal of the International Neuropsychological Society : Jins. 14: 209-21. PMID 18282319 DOI: 10.1017/S1355617708080570 |
0.359 |
|
| 2008 |
Couture SM, Penn DL, Addington J, Woods SW, Perkins DO. Assessment of social judgments and complex mental states in the early phases of psychosis. Schizophrenia Research. 100: 237-41. PMID 18255273 DOI: 10.1016/J.Schres.2007.12.484 |
0.31 |
|
| 2008 |
Cannon TD, Cadenhead K, Cornblatt B, Woods SW, Addington J, Walker E, Seidman LJ, Perkins D, Tsuang M, McGlashan T, Heinssen R. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Archives of General Psychiatry. 65: 28-37. PMID 18180426 DOI: 10.1001/Archgenpsychiatry.2007.3 |
0.439 |
|
| 2008 |
Addington J, Penn D, Woods SW, Addington D, Perkins DO. Facial affect recognition in individuals at clinical high risk for psychosis. The British Journal of Psychiatry : the Journal of Mental Science. 192: 67-8. PMID 18174514 DOI: 10.1192/Bjp.Bp.107.039784 |
0.44 |
|
| 2008 |
Addington J, Penn D, Woods SW, Addington D, Perkins DO. Social functioning in individuals at clinical high risk for psychosis. Schizophrenia Research. 99: 119-24. PMID 18023329 DOI: 10.1016/J.Schres.2007.10.001 |
0.41 |
|
| 2007 |
Hoffman RE, Woods SW, Hawkins KA, Pittman B, Tohen M, Preda A, Breier A, Glist J, Addington J, Perkins DO, McGlashan TH. Extracting spurious messages from noise and risk of schizophrenia-spectrum disorders in a prodromal population. The British Journal of Psychiatry : the Journal of Mental Science. 191: 355-6. PMID 17906248 DOI: 10.1192/Bjp.Bp.106.031195 |
0.4 |
|
| 2007 |
Keefe RS, Sweeney JA, Gu H, Hamer RM, Perkins DO, McEvoy JP, Lieberman JA. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. The American Journal of Psychiatry. 164: 1061-71. PMID 17606658 DOI: 10.1176/Ajp.2007.164.7.1061 |
0.378 |
|
| 2007 |
Keefe RS, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, Meltzer HY, Green MF, Capuano G, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Davis CE, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Archives of General Psychiatry. 64: 633-47. PMID 17548746 DOI: 10.1001/Archpsyc.64.6.633 |
0.386 |
|
| 2007 |
McGlashan TH, Addington J, Cannon T, Heinimaa M, McGorry P, O'Brien M, Penn D, Perkins D, Salokangas RK, Walsh B, Woods SW, Yung A. Recruitment and treatment practices for help-seeking "prodromal" patients. Schizophrenia Bulletin. 33: 715-26. PMID 17483100 DOI: 10.1093/Schbul/Sbm025 |
0.378 |
|
| 2007 |
Pinkham AE, Penn DL, Perkins DO, Graham KA, Siegel M. Emotion perception and social skill over the course of psychosis: a comparison of individuals "at-risk" for psychosis and individuals with early and chronic schizophrenia spectrum illness. Cognitive Neuropsychiatry. 12: 198-212. PMID 17453901 DOI: 10.1080/13546800600985557 |
0.389 |
|
| 2007 |
Lieberman JA, Perkins DO, Jarskog LF. Neuroprotection: a therapeutic strategy to prevent deterioration associated with schizophrenia. Cns Spectrums. 12: 1-13; quiz 14. PMID 17329984 DOI: 10.1017/S1092852900025906 |
0.325 |
|
| 2007 |
Swartz MS, Perkins DO, Stroup TS, Davis SM, Capuano G, Rosenheck RA, Reimherr F, McGee MF, Keefe RS, McEvoy JP, Hsiao JK, Lieberman JA. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. The American Journal of Psychiatry. 164: 428-36. PMID 17329467 DOI: 10.1176/Ajp.2007.164.3.428 |
0.383 |
|
| 2007 |
Addington J, Cadenhead KS, Cannon TD, Cornblatt B, McGlashan TH, Perkins DO, Seidman LJ, Tsuang M, Walker EF, Woods SW, Heinssen R. North American Prodrome Longitudinal Study: a collaborative multisite approach to prodromal schizophrenia research. Schizophrenia Bulletin. 33: 665-72. PMID 17255119 DOI: 10.1093/Schbul/Sbl075 |
0.434 |
|
| 2007 |
Stroup TS, McEvoy JP, Swartz MS, Hamer RM, Perkins DO, Lieberman JA. Comparison of Antipsychotics for Metabolic Problems (CAMP): A NIMH schizophrenia trials network study Clinical Schizophrenia and Related Psychoses. 1: 69-72. DOI: 10.3371/Csrp.1.1.6 |
0.38 |
|
| 2007 |
Lieberman JA, Buckley PF, Perkins DO. Neuroprotection: A New Strategy in the Treatment of Schizophrenia Cns Spectrums. 12: 1-16. DOI: 10.1017/S1092852900026328 |
0.454 |
|
| 2007 |
Perkins DO. Early Identification and Treatment of Schizophrenia Cns Spectrums. 12: 5-8. DOI: 10.1017/S1092852900025918 |
0.393 |
|
| 2006 |
Rosenheck RA, Leslie DL, Sindelar J, Miller EA, Lin H, Stroup TS, McEvoy J, Davis SM, Keefe RS, Swartz M, Perkins DO, Hsiao JK, Lieberman J. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. The American Journal of Psychiatry. 163: 2080-9. PMID 17151158 DOI: 10.1176/Ajp.2006.163.12.2080 |
0.373 |
|
| 2006 |
Keefe RS, Perkins DO, Gu H, Zipursky RB, Christensen BK, Lieberman JA. A longitudinal study of neurocognitive function in individuals at-risk for psychosis. Schizophrenia Research. 88: 26-35. PMID 16930949 DOI: 10.1016/J.Schres.2006.06.041 |
0.401 |
|
| 2006 |
Green AI, Lieberman JA, Hamer RM, Glick ID, Gur RE, Kahn RS, McEvoy JP, Perkins DO, Rothschild AJ, Sharma T, Tohen MF, Woolson S, Zipursky RB. Olanzapine and haloperidol in first episode psychosis: two-year data. Schizophrenia Research. 86: 234-43. PMID 16887334 DOI: 10.1016/J.Schres.2006.06.021 |
0.412 |
|
| 2006 |
Perkins DO. Clinical trials in schizophrenia with results for the real world. Cns Spectrums. 11: 9-13. PMID 16816795 DOI: 10.1017/S1092852900026638 |
0.343 |
|
| 2006 |
McEvoy JP, Johnson J, Perkins D, Lieberman JA, Hamer RM, Keefe RS, Tohen M, Glick ID, Sharma T. Insight in first-episode psychosis. Psychological Medicine. 36: 1385-93. PMID 16740175 DOI: 10.1017/S0033291706007793 |
0.339 |
|
| 2006 |
McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, Woods SW, Hawkins KA, Hoffman RE, Preda A, Epstein I, Addington D, Lindborg S, Trzaskoma Q, Tohen M, Breier A. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. The American Journal of Psychiatry. 163: 790-9. PMID 16648318 DOI: 10.1176/Ajp.2006.163.5.790 |
0.401 |
|
| 2006 |
Keefe RS, Bilder RM, Harvey PD, Davis SM, Palmer BW, Gold JM, Meltzer HY, Green MF, Miller DD, Canive JM, Adler LW, Manschreck TC, Swartz M, Rosenheck R, Perkins DO, et al. Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 31: 2033-46. PMID 16641947 DOI: 10.1038/Sj.Npp.1301072 |
0.436 |
|
| 2006 |
Perkins DO. Review: longer duration of untreated psychosis is associated with worse outcome in people with first episode psychosis. Evidence-Based Mental Health. 9: 36. PMID 16638885 DOI: 10.1136/Ebmh.9.2.36 |
0.318 |
|
| 2006 |
Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Rosenheck RA, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. The American Journal of Psychiatry. 163: 611-22. PMID 16585435 DOI: 10.1176/Appi.Ajp.163.4.611 |
0.401 |
|
| 2006 |
Perkins DO, Johnson JL, Hamer RM, Zipursky RB, Keefe RS, Centorrhino F, Green AI, Glick IB, Kahn RS, Sharma T, Tohen M, McEvoy JP, Weiden PJ, Lieberman JA. Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode. Schizophrenia Research. 83: 53-63. PMID 16529910 DOI: 10.1016/J.Schres.2005.10.016 |
0.343 |
|
| 2006 |
Rosenheck R, Leslie D, Keefe R, McEvoy J, Swartz M, Perkins D, Stroup S, Hsiao JK, Lieberman J. Barriers to employment for people with schizophrenia. The American Journal of Psychiatry. 163: 411-7. PMID 16513861 DOI: 10.1176/Appi.Ajp.163.3.411 |
0.418 |
|
| 2006 |
Rosenheck R, Stroup S, Keefe RS, McEvoy J, Swartz M, Perkins D, Hsiao J, Shumway M, Lieberman J. Measuring outcome priorities and preferences in people with schizophrenia. The British Journal of Psychiatry : the Journal of Mental Science. 187: 529-36. PMID 16319405 DOI: 10.1192/Bjp.187.6.529 |
0.336 |
|
| 2006 |
McEvoy J, Perkins D, Gu H, Hamer R, Lieberman J. 0394 CLINICAL EFFECTIVENESS AND PREDICTORS OF TREATMENT NON-ADHERENCE: COMPARISON OF OLANZAPINE, QUETIAPINE, AND RISPERIDONE IN FIRST-EPISODE PSYCHOSIS Schizophrenia Research. 86: S130. DOI: 10.1016/S0920-9964(06)70390-5 |
0.364 |
|
| 2006 |
Perkins D, Gu H, Zipursky R, Gerig G, Lieberman J. TC18C MRI OF BRAIN VOLUMES AT THE PRODROME AND FIRST EPISODE STAGES OF SCHIZOPHRENIA Schizophrenia Research. 86: S59. DOI: 10.1016/S0920-9964(06)70176-1 |
0.347 |
|
| 2006 |
Hoffman RE, Woods S, Preda A, Tohen M, Breier A, Glist J, Addington J, Perkins DO, Hawkins K, McGlashan TH. Tc3A Excessive Top-Down Perceptual Processing And Reduced Real-World Investment Exhibited By Prodromal Patients Predict Subsequent Conversion To Schizophrenia Schizophrenia Research. 86. DOI: 10.1016/S0920-9964(06)70137-2 |
0.37 |
|
| 2006 |
Seidman L, Cornblatt B, Addington J, Cadenhead K, Cannon T, McGlashan T, Perkins D, Walker E, Woods S, Tsuang M, Heinssen R. WC8B NEUROCOGNITIVE FUNCTIONING IN THE PRODROME TO PSYCHOSIS FROM THE NAPLS COLLABORATION Schizophrenia Research. 86: S17. DOI: 10.1016/S0920-9964(06)70051-2 |
0.308 |
|
| 2006 |
Perkins DO. What have we learned from CATIE about the pharmacologic treatment of schizophrenia? Current Psychosis and Therapeutics Reports. 4: 35-39. DOI: 10.1007/Bf02629412 |
0.418 |
|
| 2005 |
Perkins DO, Gu H, Boteva K, Lieberman JA. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. The American Journal of Psychiatry. 162: 1785-804. PMID 16199825 DOI: 10.1176/Appi.Ajp.162.10.1785 |
0.373 |
|
| 2005 |
Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England Journal of Medicine. 353: 1209-23. PMID 16172203 DOI: 10.1056/Nejmoa051688 |
0.32 |
|
| 2005 |
Pinkham A, Penn D, Wangelin B, Perkins D, Gerig G, Gu H, Lieberman J. Facial emotion perception and fusiform gyrus volume in first episode schizophrenia. Schizophrenia Research. 79: 341-3. PMID 16125902 DOI: 10.1016/J.Schres.2005.07.012 |
0.336 |
|
| 2005 |
Lieberman JA, Tollefson GD, Charles C, Zipursky R, Sharma T, Kahn RS, Keefe RS, Green AI, Gur RE, McEvoy J, Perkins D, Hamer RM, Gu H, Tohen M. Antipsychotic drug effects on brain morphology in first-episode psychosis. Archives of General Psychiatry. 62: 361-70. PMID 15809403 DOI: 10.1001/Archpsyc.62.4.361 |
0.373 |
|
| 2005 |
Morey RA, Inan S, Mitchell TV, Perkins DO, Lieberman JA, Belger A. Imaging frontostriatal function in ultra-high-risk, early, and chronic schizophrenia during executive processing. Archives of General Psychiatry. 62: 254-62. PMID 15753238 DOI: 10.1001/Archpsyc.62.3.254 |
0.401 |
|
| 2005 |
Judge AM, Perkins DO, Nieri J, Penn DL. Pathways to care in first episode psychosis: A pilot study on help-seeking precipitants and barriers to care Journal of Mental Health. 14: 465-469. DOI: 10.1080/09638230500271089 |
0.303 |
|
| 2004 |
Perkins DO. Evaluating and treating the prodromal stage of schizophrenia. Current Psychiatry Reports. 6: 289-95. PMID 15260945 DOI: 10.1007/S11920-004-0079-8 |
0.406 |
|
| 2004 |
Perkins DO, Lieberman JA, Gu H, Tohen M, McEvoy J, Green AI, Zipursky RB, Strakowski SM, Sharma T, Kahn RS, Gur R, Tollefson G. Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders British Journal of Psychiatry. 185: 18-24. PMID 15231551 DOI: 10.1192/Bjp.185.1.18 |
0.451 |
|
| 2004 |
Hawkins KA, McGlashan TH, Quinlan D, Miller TJ, Perkins DO, Zipursky RB, Addington J, Woods SW. Factorial structure of the Scale of Prodromal Symptoms. Schizophrenia Research. 68: 339-47. PMID 15099615 DOI: 10.1016/S0920-9964(03)00053-7 |
0.382 |
|
| 2004 |
Hawkins KA, Addington J, Keefe RS, Christensen B, Perkins DO, Zipurksy R, Woods SW, Miller TJ, Marquez E, Breier A, McGlashan TH. Neuropsychological status of subjects at high risk for a first episode of psychosis. Schizophrenia Research. 67: 115-22. PMID 14984870 DOI: 10.1016/J.Schres.2003.08.007 |
0.417 |
|
| 2003 |
Miller TJ, McGlashan TH, Rosen JL, Cadenhead K, Cannon T, Ventura J, McFarlane W, Perkins DO, Pearlson GD, Woods SW. Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. Schizophrenia Bulletin. 29: 703-15. PMID 14989408 DOI: 10.1093/Oxfordjournals.Schbul.A007040 |
0.367 |
|
| 2003 |
Bradford DW, Perkins DO, Lieberman JA. Pharmacological Management of First-Episode Schizophrenia and Related Nonaffective Psychoses Drugs. 63: 2265-2283. PMID 14524730 DOI: 10.2165/00003495-200363210-00001 |
0.444 |
|
| 2003 |
Woods SW, Breier A, Zipursky RB, Perkins DO, Addington J, Miller TJ, Hawkins KA, Marquez E, Lindborg SR, Tohen M, McGlashan TH. Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biological Psychiatry. 54: 453-64. PMID 12915290 DOI: 10.1016/S0006-3223(03)00321-4 |
0.353 |
|
| 2003 |
Swartz MS, Perkins DO, Stroup TS, McEvoy JP, Nieri JM, Haak DC. Assessing clinical and functional outcomes in the clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial Schizophrenia Bulletin. 29: 33-43. PMID 12908659 DOI: 10.1093/Oxfordjournals.Schbul.A006989 |
0.416 |
|
| 2003 |
Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE, Kahn R, McEvoy J, Perkins D, Sharma T, Zipursky R, Wei H, Hamer RM. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. The American Journal of Psychiatry. 160: 1396-404. PMID 12900300 DOI: 10.1176/Appi.Ajp.160.8.1396 |
0.429 |
|
| 2003 |
Pinkham AE, Penn DL, Perkins DO, Lieberman J. Implications for the neural basis of social cognition for the study of schizophrenia. The American Journal of Psychiatry. 160: 815-24. PMID 12727681 DOI: 10.1176/Appi.Ajp.160.5.815 |
0.378 |
|
| 2003 |
Kahn R, Lieberman J, Charles C, Sharma T, Zipursky R, Gur R, Tohen M, Green A, McEvoy J, Perkins D, Hamer R, Nemeroff C, Rothschild A, Kuldau J, Strakowski S, et al. P.2.131 Antipsychotic treatment effects on progression of brain pathomorphology in first episode schizophrenia European Neuropsychopharmacology. 13: S337. DOI: 10.1016/S0924-977X(03)92084-0 |
0.378 |
|
| 2003 |
Sharma T, Lieberman J, McEvoy J, Perkins D, Hamer R, Zipursky R, Kahn R, Gur R, Centorrino F, Glick I, Green A, Nemeroff C, Rothschild A, Strakowski S, Tohen M, et al. S.14.05 Long-term efficacy and safety of atypical and conventional antipsychotic drugs in first episode schizophrenia European Neuropsychopharmacology. 13: S134-S135. DOI: 10.1016/S0924-977X(03)91655-5 |
0.331 |
|
| 2003 |
McGlashan TH, Zipursky RB, Perkins DO, Addington J, Woods SW, Miller TJ, Lindborg S, Marquez E, Hawkins K, Hoffman RE, Tohen M, Breier A. Olanzapine versus placebo treatment of the schizophrenia prodrome: One year results Schizophrenia Research. 60: 295. DOI: 10.1016/S0920-9964(03)80497-8 |
0.394 |
|
| 2003 |
Lieberman J, Charles HC, Sharma T, Zipursky R, Kahn R, Gur R, Tohen M, Green AI, McEvoy J, Perkins D, Hamer RM, Nemeroff C, Rothschild A, Kuldau J, Strakowski S, et al. Antipsychotic treatment effects on progression of brain pathomorphology in first episode schizophrenia Schizophrenia Research. 60: 293. DOI: 10.1016/S0920-9964(03)80491-7 |
0.382 |
|
| 2003 |
McEvoy J, Lieberman J, Perkins D, Hamer R, Sharma T, Zipursky R, Kahn R, Gur R, Centorrino F, Glick I, Green A, Nemeroff C, Rothschild A, Strakowski S, Tohen M, et al. Long-term efficacy and safety of atypical and conventional antipsychotic drugs in first episode schizophrenia Schizophrenia Research. 60: 313. DOI: 10.1016/S0920-9964(03)80257-8 |
0.333 |
|
| 2003 |
Woods SW, Breier A, Zipursky RB, Perkins DO, Addington J, Miller TJ, Hawkins KA, Marquez E, Lindborg SR, Tohen M, McGlashan TH. Olanzapine versus placebo for prodromal symptoms Schizophrenia Research. 60: 306-307. DOI: 10.1016/S0920-9964(03)80236-0 |
0.312 |
|
| 2003 |
Zipursky R, Gu H, Green A, Centorrina F, Glick I, Perkins D, McEvoy J, Sharma T, Gur R, Strakowski S, Kahn R, Nemeroff C, Rothschild A, Lieberman J. Clinical correlates of weight gain in first episode psychosis patients treated with olanzapine Schizophrenia Research. 60: 372. DOI: 10.1016/S0920-9964(03)80215-3 |
0.302 |
|
| 2002 |
Perkins DO. Predictors of noncompliance in patients with schizophrenia Journal of Clinical Psychiatry. 63: 1121-1128. PMID 12523871 DOI: 10.4088/Jcp.V63N1206 |
0.417 |
|
| 2002 |
Leserman J, Petitto JM, Gu H, Gaynes BN, Barroso J, Golden RN, Perkins DO, Folds JD, Evans DL. Progression to AIDS, a clinical AIDS condition and mortality: psychosocial and physiological predictors. Psychological Medicine. 32: 1059-73. PMID 12214787 DOI: 10.1017/S0033291702005949 |
0.316 |
|
| 2002 |
Lieberman JA, Perkins D, Belger A, Chakos M, Jarskog F, Boteva K, Gilmore J. Erratum: The early stages of schizophrenia: Speculations on pathogenesis, pathophysiology, and therapeuthic approaches (Biological Psychiatry 50:11 (884-897)) Biological Psychiatry. 51. DOI: 10.1016/S0006-3223(02)01310-0 |
0.354 |
|
| 2001 |
Heinssen RK, Perkins DO, Appelbaum PS, Fenton WS. Informed Consent in Early Psychosis Research: National Institute of Mental Health workshop, November 15, 2000 Schizophrenia Bulletin. 27: 571-584. PMID 11824484 DOI: 10.1093/Oxfordjournals.Schbul.A006897 |
0.393 |
|
| 2001 |
Lieberman JA, Perkins D, Belger A, Chakos M, Jarskog F, Boteva K, Gilmore J. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biological Psychiatry. 50: 884-97. PMID 11743943 DOI: 10.1016/S0006-3223(01)01303-8 |
0.448 |
|
| 2000 |
Leserman J, Petitto JM, Golden RN, Gaynes BN, Gu H, Perkins DO, Silva SG, Folds JD, Evans DL. Impact of stressful life events, depression, social support, coping, and cortisol on progression to AIDS. The American Journal of Psychiatry. 157: 1221-8. PMID 10910783 DOI: 10.1176/Appi.Ajp.157.8.1221 |
0.309 |
|
| 2000 |
Perkins DO, Leserman J, Jarskog LF, Graham K, Kazmer J, Lieberman JA. Characterizing and dating the onset of symptoms in psychotic illness: The Symptom Onset in Schizophrenia (SOS) inventory Schizophrenia Research. 44: 1-10. PMID 10867307 DOI: 10.1016/S0920-9964(99)00161-9 |
0.431 |
|
| 2000 |
Perkins DO, Leserman J, Graham K, Kazmer J, Jeffrey FJ, Lieberman A. The symptom onset in schizophrenia (SOS) scale: Test-retest reliability Schizophrenia Research. 41: 179. DOI: 10.1016/S0920-9964(00)90734-5 |
0.379 |
|
| 1999 |
Keefe RSE, Silva SG, Perkins DO, Lieberman JA. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: A review and meta-analysis Schizophrenia Bulletin. 25: 201-222. PMID 10416727 DOI: 10.1093/Oxfordjournals.Schbul.A033374 |
0.411 |
|
| 1998 |
Jarskog LF, Perkins DO, Graham KA, Broadwell S, Regan JJ. 390. Nerve growth factor levels in schizophrenia in response to stress Biological Psychiatry. 43. DOI: 10.1016/S0006-3223(98)90838-1 |
0.314 |
|
| 1996 |
Gilmore JH, Perkins DO, Kliewer MA, Hage ML, Silva SG, Chescheir NC, Hertzberg BS, Sears CA. Fetal brain development of twins assessed in utero by ultrasound: Implications for schizophrenia Schizophrenia Research. 19: 141-149. PMID 8789912 DOI: 10.1016/0920-9964(95)00099-2 |
0.364 |
|
| 1993 |
Gilmore J, Perkins D, Lindsey B. Patients with schizophrenia in a general hospital: Reasons for psychiatric consultation Schizophrenia Research. 9: 132-133. DOI: 10.1016/0920-9964(93)90215-5 |
0.351 |
|
| Show low-probability matches. |